KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Non Operating Income (2018 - 2025)

Historic Other Non Operating Income for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $677000.0.

  • Esperion Therapeutics' Other Non Operating Income fell 5726.01% to $677000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $732000.0, marking a year-over-year increase of 10153.16%. This contributed to the annual value of -$54.9 million for FY2024, which is 113795.12% down from last year.
  • Esperion Therapeutics' Other Non Operating Income amounted to $677000.0 in Q3 2025, which was down 5726.01% from $666000.0 recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Other Non Operating Income ranged from a high of $3.9 million in Q4 2021 and a low of -$53.2 million during Q2 2024
  • For the 5-year period, Esperion Therapeutics' Other Non Operating Income averaged around -$1.9 million, with its median value being $677000.0 (2025).
  • As far as peak fluctuations go, Esperion Therapeutics' Other Non Operating Income surged by 1631250.0% in 2021, and later tumbled by 330692.77% in 2024.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Other Non Operating Income stood at $3.9 million in 2021, then tumbled by 65.6% to $1.4 million in 2022, then decreased by 20.3% to $1.1 million in 2023, then tumbled by 255.83% to -$1.7 million in 2024, then skyrocketed by 140.23% to $677000.0 in 2025.
  • Its last three reported values are $677000.0 in Q3 2025, $666000.0 for Q2 2025, and $1.1 million during Q1 2025.